Colorectal cancer in primary sclerosing cholangitis patients with ulcerative colitis is mostly right-sided where carcinogenic secondary bile acids are highest.
Dr Lashner and colleagues from Ohio investigated whether ursodeoxycholic acid could be chemopreventive for colorectal cancer.
A historical cohort study was performed on primary sclerosing cholangitis patients with ulcerative colitis.
The investigators compared 28 patients who were treated with ursodeoxycholic acid for at least 6 months with the 92 patients not treated.
|The adjusted relative risk of developing dysplasia or cancer was 0.6|
|Alimentary Pharmacology & Therapeutics|
The primary outcomes were colorectal cancer and dysplasia.
The investigative team's secondary outcome was overall mortality.
The investigators found that the cumulative incidence of dysplasia or cancer was not significantly different between cases and controls.
The adjusted relative risk for cases of developing dysplasia or cancer was 0.60.
The team noted that the cumulative mortality was significantly different between groups.
The adjusted relative risk for cases of death was 0.44.<./p>
Dr Lashner's team commented, “In ulcerative colitis patients with primary sclerosing cholangitis, ursodeoxycholic acid did not reduce the risk of developing cancer or dysplasia.”
However, ursodeoxycholic acid may reduce mortality.”